KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.

Giacomo Biganzoli, Edoardo Isnaldi, François Richard, Giuseppe Marano, Patrizia Boracchi, Marion Maetens, Giuseppe Floris, Patrick Neven, Guy Jerusalem, Elisabetta Munzone, Erika Hitre, Andrea Gombos, Alastair Thompson, Stefan Aebi, Roswitha Kammler, Patrizia Dell'Orto, Giuseppe Viale, Meredith M Regan, Marco Colleoni, Elia Biganzoli, Christine Desmedt

Eur J Cancer 222 115438

PMID40286474
PMCIDPMC12118534
DOI10.1016/j.ejca.2025.115438
发表日期2025-04-26
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Obesity is associated with a greater risk of developing distant recurrences in patients with estrogen receptor-positive (ER+) breast cancer. This association is however poorly investigated in patients treated with extended endocrine treatment (ET). We therefore evaluated the prognostic role of BMI in the SOLE trial, where postmenopausal patients, after having completed 4-6 years of adjuvant ET, were treated with 5 additional years of continuous or intermittent letrozole. PATIENTS & METHODS: We considered the 3606 patients with ER+ /HER2- lymph node-positive BC with available BMI from the SOLE trial (NCT00553410). Distant-recurrence free interval (DRFI) was the main endpoint, and breast cancer-free interval (BCFI), disease-free survival (DFS) and overall survival (OS) secondary endpoints. Adjusted risk ratios (RR) for distant metastases were estimated with crude cumulative incidence models. RESULTS: 38.6 % of the patients were underweight or normal weight, 36.5 % overweight and 24.9 % obese. BMI was associated with age, tumor size, number of positive lymph nodes, menopausal status and type of prior ET. In the adjusted analyses, the prognostic value of BMI was dependent on prior ET and extended ET arm (second-order interaction p-value<0.001 for DRFI, BCFI and DFS, but not for OS). For instance, in patients treated with both a selective estrogen receptor modulator and an aromatase inhibitor in the first five years, obesity, as compared to normal-weight, was associated with better (RRDRFI=0.61, 95 %CI: 0.42-0.90) and worse (RRDRFI=2.31, 95 %CI: 1.41-3.78) outcomes in the adjusted models, in patients treated with continuous and intermittent letrozole in the extended ET, respectively. CONCLUSION: We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. This warrants further investigation.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

Fig. 3

Fig. 3 Prognostic association of categorical BMI with BCFI. ( A) Unadjusted non-parametrical estimates of CCI of BC recurrences conditioned on prior endocrine treatment, treatment arm and BMI category. (B) Forest plot of the estimated risk ratios of BC recurrences between patients with normal weight and overweight (blue) and between patients with normal weight and obesity (purple) adjusted for tumor size, grade, histology, number of positive lymph nodes, and age. Patients with normal weight are the reference category. (C) Estimated risk ratios for the other covariates in the multivariable model: tumor grade, tumor size, histology, and number of positive lymph nodes. (D) Plot of the non-linear effect of age, modelled with a restricted cubic spline. The risk ratios (solid line) are computed with respect to a subject of 53 years of age as the reference. Dashed lines represent the 95 % CIs. Abbreviations: BC: breast cancer; BCFI: breast cancer free interval; BMI: body mass index; CCI: crude cumulative incidence; CIs: confidence intervals.

A

Crude cumulative incidence

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:frequent upward jumps曲线 1:extreme upward reversal曲线 2:short span曲线 2:very low support
查看结果
A_2

Crude cumulative incidence

Fig. 3 · Panel A_2

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel A_2 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
A_3

Crude cumulative incidence

Fig. 3 · Panel A_3

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel A_3 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme jump
查看结果
A_4

Incidence

Fig. 3 · Panel A_4

failed 待 EXE 对齐 预期 3 条 已提取 0 条

Panel A_4 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 0 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
No curves extracted
查看结果
A_5

Incidence

Fig. 3 · Panel A_5

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel A_5 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 2:frequent upward jumps曲线 3:frequent upward jumps曲线 3:extreme jump
查看结果
A_6

Incidence

Fig. 3 · Panel A_6

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A_6 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start曲线 3:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Overview of the SOLE trial design and patient cohort for this retrospective analysis. Abbreviations: AI: aromatase inhibitor, BMI: body mass index, ER: estrogen receptor, SERM: Selective Estrogen Receptor Modulator.
非 KM Figure
Fig. 2Fig. 2 Prognostic association of categorical BMI with DRFI. ( A) Unadjusted non-parametrical estimates of CCI of distant recurrences conditioned on prior endocrine treatment, treatment arm and BMI category. (B) Forest plot of the estimated risk ratios of distant recurrences between patients with normal weight and overweight (blue) and between patients with normal weight and obesity (purple) adjusted for tumor size, grade, histology, number of positive lymph nodes, and age. Patients with normal weight are the reference category. (C) Estimated risk ratios for the other covariates in the multivariable model: tumor grade, tumor size, histology, and number of positive lymph nodes. (D) Plot of the non-linear effect of age, modelled with a restricted cubic spline. The risk ratios (solid line) are computed with respect to a subject of 53 years of age as the reference. Dashed lines represent the 95 % CIs. Abbreviations: BMI: body mass index; CCI: crude cumulative incidence; CIs: confidence intervals.
非 KM Figure